Clene

Clene Net Change in Cash

The Net Change in Cash of Clene (CLNN) as of Nov 16, 2026 is -6.97 M USD. In the previous year, Net Change in Cash was -16.67 M USD — a change of -58.20% (higher).

Net Change in Cash

-6.97 MUSD

YoY

-58.20%

Last updated:

Net Change in Cash of Clene is 2025 -6.97 M USD. Net Change in Cash of Clene was 2024 -16.67 M USD. It decreases by -58.20% higher compared to the previous year.

The Clene Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
787,783.00 USD
Jan 1, 2019
-7.99 M USD
Jan 1, 2020
50.49 M USD
Jan 1, 2021
-8.93 M USD
Jan 1, 2022
-31.96 M USD
Jan 1, 2023
10.49 M USD
Jan 1, 2024
-16.67 M USD
Jan 1, 2025
-6.97 M USD
The Clene Net Change in Cash history
YEARNet Change in CashYoY
-6.97 MUSD-58.20%
-16.67 MUSD-258.89%
10.49 MUSD-132.82%
-31.96 MUSD+257.89%
-8.93 MUSD-117.69%
50.49 MUSD-731.96%
-7.99 MUSD-1,114.11%
787,783.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc develops therapeutic products for neurodegenerative diseases, focusing on targeting energetic failure as a root cause. Its primary product CNM-Au8 is an oral suspension of gold nanocrystals designed to restore neuronal health by enhancing energy production and utilization. The company also develops CNM-ZnAg, a spectrum antiviral and antibacterial agent containing zinc and silver ions for infectious disease treatment and immune support, and CNM-AgZn17, a gel polymer suspension of zinc and silver for wound healing and infectious disease management. These products are intended for clinical development and eventual commercialization in the pharmaceutical market. Clene's target customers are patients suffering from neurodegenerative diseases and infectious conditions requiring antiviral, antibacterial, or wound healing solutions. The company's products aim to address unmet medical needs in these therapeutic areas by leveraging innovative nanocrystal and ion-based technologies. The firm operates within the biopharmaceutical sector, developing treatments that focus on cellular energy processes to provide neuroprotection and remyelination. The company generates revenue through the development and potential future commercialization of its drug candidates. CNM-Au8 targets neurodegenerative diseases by addressing energetic failure, while CNM-ZnAg and CNM-AgZn17 focus on infectious disease treatment and wound healing applications. These products are in clinical development stages, with the company seeking to advance them toward regulatory approval and market entry. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Net Change in Cash of Clene is -6.97 M USD in 2025.

Net Change in Cash of Clene changed from -16.67 M USD to -6.97 M USD, representing a -58.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Clene since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Clene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Clene

All Key Metrics — Clene